Insider Selling: Ophthotech Corp (OPHT) SVP Sells 5,289 Shares of Stock

Ophthotech Corp (NASDAQ:OPHT) SVP Barbara A. Wood sold 5,289 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $3.19, for a total value of $16,871.91. Following the transaction, the senior vice president now owns 20,472 shares in the company, valued at $65,305.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Ophthotech Corp (NASDAQ OPHT) traded up $0.03 during trading on Wednesday, hitting $3.30. The stock had a trading volume of 361,437 shares, compared to its average volume of 558,700. Ophthotech Corp has a 1-year low of $2.24 and a 1-year high of $5.25. The stock has a market capitalization of $118.93, a price-to-earnings ratio of 2.12 and a beta of 1.58.

Several institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of Ophthotech by 3.2% during the first quarter. Geode Capital Management LLC now owns 240,571 shares of the biopharmaceutical company’s stock worth $880,000 after acquiring an additional 7,501 shares during the period. Federated Investors Inc. PA increased its position in shares of Ophthotech by 102.3% during the second quarter. Federated Investors Inc. PA now owns 55,461 shares of the biopharmaceutical company’s stock worth $142,000 after acquiring an additional 28,040 shares during the period. Schwab Charles Investment Management Inc. increased its position in shares of Ophthotech by 73.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 118,166 shares of the biopharmaceutical company’s stock worth $433,000 after acquiring an additional 49,928 shares during the period. Stonepine Capital Management LLC increased its position in shares of Ophthotech by 1.7% during the second quarter. Stonepine Capital Management LLC now owns 3,576,189 shares of the biopharmaceutical company’s stock worth $9,155,000 after acquiring an additional 59,700 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in shares of Ophthotech by 28.1% during the second quarter. Goldman Sachs Group Inc. now owns 652,992 shares of the biopharmaceutical company’s stock worth $1,672,000 after acquiring an additional 143,349 shares during the period. 62.48% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have commented on OPHT shares. Stifel Nicolaus restated a “hold” rating and set a $4.00 price target on shares of Ophthotech in a research note on Thursday, September 21st. ValuEngine upgraded Ophthotech from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Zacks Investment Research upgraded Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price target on the stock in a research note on Monday, November 13th. Finally, TheStreet upgraded Ophthotech from an “e+” rating to a “c” rating in a research note on Thursday, November 30th.

TRADEMARK VIOLATION WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/03/insider-selling-ophthotech-corp-opht-svp-sells-5289-shares-of-stock.html.

Ophthotech Company Profile

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Insider Buying and Selling by Quarter for Ophthotech (NASDAQ:OPHT)

Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply